NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity

Journal of Neuroscience

Volumn 29, Issue 38, 2009, Pages 11965-11972

  Li, Bo ^b   Devidze, Nino ^a   Barengolts, Denis ^a   Prostak, Naseem ^c   Sphicas, Eleana ^a   Apicella, Alfonso J ^b   Malinow, Roberto ^d   Emamian, Effat S ^a,e  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^c Cell and Molecular Technologies   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Advanced Technologies for Novel Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMPA RECEPTOR; GLUTAMATE RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1 S897; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SOCIAL INTERACTION; SYNAPTIC TRANSMISSION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; GENE KNOCK-IN TECHNIQUES; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; MUTATION, MISSENSE; NEURONAL PLASTICITY; NEURONS; PHOSPHORYLATION; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 70349321527     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2109-09.2009     Document Type: Article

References (63)

1. Abbott C, Bustillo J (2006) What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr Opin Psychiatry 19:135-139. (Pubitemid 44406123)
2. Adesnik H, Li G, During MJ, Pleasure SJ, Nicoll RA (2008) NMDA receptors inhibit synapse unsilencing during brain development. Proc Natl Acad Sci U S A 105:5597-5602. (Pubitemid 351753908)
3. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156:1646-1649. (Pubitemid 29460002)
4. Barria A, Malinow R (2002) Subunit-specific NMDA receptor trafficking to synapses. Neuron 35:345-353. (Pubitemid 34876735)
5. Beneyto M, Meador-Woodruff JH (2008) Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33:2175-2186. (Pubitemid 351992080)
6. Bressan RA, Pilowsky LS (2000) Imaging the glutamatergic system in vivo - relevance to schizophrenia. Eur J Nucl Med 27:1723-1731.
7. 123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biol Psychiatry 58:41-46.
8. Brown WJ, Farquhar MG (1989) Immunoperoxidase methods for the localization of antigens in cultured cells and tissue sections by electron microscopy. Methods Cell Biol 31:553-569.
9. Chen BS, Roche KW (2007) Regulation of NMDA receptors by phosphorylation. Neuropharmacology 53:362-368.
10. Choleris E, Gustafsson JA, Korach KS, Muglia LJ, Pfaff DW, Ogawa S (2003) An estrogen-dependent four-gene micronet regulating social recognition: a study with oxytocin and estrogen receptor-alpha and -beta knockout mice. Proc Natl Acad Sci U S A 100:6192-6197. (Pubitemid 36581861)
11. Constantine-Paton M, Cline HT (1998) LTP and activity-dependent synaptogenesis: the more alike they are, the more different they become. Curr Opin Neurobiol 8:139-148. (Pubitemid 28151868)
12. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:365-384.
13. Coyle JT, Tsai G (2004) NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 59:491-515. (Pubitemid 39752426)
14. Coyle JT, Tsai G, Goff D (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 1003:318-327. (Pubitemid 38083065)
15. Eastwood SL (2004) The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame? Int Rev Neurobiol 59:47-72.
16. Ellenbroek BA, Cools AR (2000) Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11:223-233. (Pubitemid 30449754)
17. Emamian ES, Karayiorgou M, Gogos JA (2004a) Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. J Neurosci 24:1561-1564. (Pubitemid 38240950)
18. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004b) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36:131-137. (Pubitemid 38174370)
19. Engblom D, Bilbao A, Sanchis-Segura C, Dahan L, Perreau-Lenz S, Balland B, Parkitna JR, Luján R, Halbout B, Mameli M, Parlato R, Sprengel R, Lüscher C, Schütz G, Spanagel R (2008) Glutamate receptors on dopamine neurons control the persistence of cocaine seeking. Neuron 59:497-508.
20. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154. (Pubitemid 32702206)
21. Geyer MA, McIlwain KL, Paylor R (2002) Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry 7:1039-1053.
22. Giakoumaki SG, Roussos P, Rogdaki M, Karli C, Bitsios P, Frangou S (2007) Evidence of disrupted prepulse inhibition in unaffected siblings of bipolar disorder patients. Biol Psychiatry 62:1418-1422. (Pubitemid 350180720)
23. Grimwood S, Slater P, Deakin JF, Hutson PH (1999) NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport 10:461-465. (Pubitemid 29333265)
24. Hall BJ, Ripley B, Ghosh A (2007) NR2B signaling regulates the development of synaptic AMPA receptor current. J Neurosci 27:13446-13456. (Pubitemid 350255329)
25. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68; image 45.
26. Harrison PJ, Law AJ, Eastwood SL (2003) Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann N Y Acad Sci 1003:94-101.
27. Horiuchi Y, Ishiguro H, Koga M, Inada T, Iwata N, Ozaki N, Ujike H, Muratake T, Someya T, Arinami T (2007) Support for association of the PPP3CC gene with schizophrenia. Mol Psychiatry 12:891-893. (Pubitemid 47482698)
28. Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9:984-997:979.
29. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
30. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajós M (2008) Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 7:68-83.
31. Kessels HW, Malinow R (2009) Synaptic AMPA receptor plasticity and behavior. Neuron 61:340-350.
32. Kinoshita Y, Ikeda M, Ujike H, Kitajima T, Yamanouchi Y, Aleksic B, Kishi T, Kawashima K, Ohkouchi T, Ozaki N, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Sekine Y, Iyo M, Sora I, Iwata N (2008) Association study of the calcineurin A gamma subunit gene (PPP3CC) and methamphetamineuse disorder in a Japanese population. Ann N Y Acad Sci 1139:57-62.
33. Konradi C, Heckers S (2003) Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97:153-179. (Pubitemid 36138820)
34. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
35. Lau CG, Zukin RS (2007) NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 8:413-426. (Pubitemid 46789232)
36. Li B, Woo RS, Mei L, Malinow R (2007) The Neuregulin-1 receptor ErbB4 controls glutamatergic synapse maturation and plasticity. Neuron 54:583-597. (Pubitemid 46756136)
37. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150. (Pubitemid 27365955)
38. Malinow R, Malenka RC (2002) AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25:103-126. (Pubitemid 34748013)
39. Matsui T, Sekiguchi M, Hashimoto A, Tomita U, Nishikawa T, Wada K (1995) Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J Neurochem 65:454-458.
40. Millan MJ (2005) N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 179:30-53.
41. 2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol Pharmacol 71:1598-1609.
42. Moy SS, Nadler JJ (2008) Advances in behavioral genetics: mouse models of autism. Mol Psychiatry 13:4-26. (Pubitemid 350275186)
43. Nudmamud S, Reynolds GP (2001) Increased density of glutamate/N-methyl-D- aspartate receptors in superior temporal cortex in schizophrenia. Neurosci Lett 304:9-12.
44. Pietraszek M (2003) Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. Pol J Pharmacol 55:133-154.
45. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, Ell PJ (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11:118-119. (Pubitemid 43164609)
46. Powell CM, Miyakawa T (2006) Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry 59:1198-1207.
47. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006) Neurobiology of schizophrenia. Neuron 52:139-153.
48. Sawa A, Snyder SH (2005) Genetics. Two genes link two distinct psychoses. Science 310:1128-1129.
49. Scott DB, Blanpied TA, Ehlers MD (2003) Coordinated PKA and PKC phosphorylation suppresses RXR-mediated ER retention and regulates the surface delivery of NMDA receptors. Neuropharmacology 45:755-767.
50. Sheng M, Kim MJ (2002) Postsynaptic signaling and plasticity mechanisms. Science 298:776-780.
51. Shi SH, Hayashi Y, Petralia RS, Zaman SH, Wenthold RJ, Svoboda K, Malinow R (1999) Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science 284:1811-1816. (Pubitemid 29275615)
52. Snyder GL, Galdi S, Hendrick JP, Hemmings HC Jr (2007) General anesthetics selectively modulate glutamatergic and dopaminergic signaling via site-specific phosphorylation in vivo. Neuropharmacology 53:619-630. (Pubitemid 47513168)
53. Standley S, Roche KW, McCallum J, Sans N, Wenthold RJ (2000) PDZ domain suppression of an ER retention signal in NMDA receptor NR1 splice variants. Neuron 28:887-898. (Pubitemid 32038079)
54. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, et al. (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877-892.
55. Swerdlow NR, Geyer MA (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24:285-301.
56. Thaker GK, Carpenter WT Jr (2001) Advances in schizophrenia. Nat Med 7:667-671.
57. Tingley WG, Ehlers MD, Kameyama K, Doherty C, Ptak JB, Riley CT, Huganir RL (1997) Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem 272:5157-5166.
58. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998) D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089. (Pubitemid 28547143)
59. Tuominen HJ, Tiihonen J, Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72:225-234. (Pubitemid 39550993)
60. Xia H, Hornby ZD, Malenka RC (2001) An ER retention signal explains differences in surface expression of NMDA and AMPA receptor subunits. Neuropharmacology 41:714-723. (Pubitemid 32972188)
61. Xu DD, Mo ZX, Yung KK, Yang Y, Leung AW (2006) Individual and combined effects of methamphetamine and ketamine on conditioned place preference and NR1 receptor phosphorylation in rats. Neurosignals 15:322-331.
62. Yee BK, Chang DL, Feldon J (2004) Theeffects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57BL6 mice. Neuropsychopharmacology 29:1865-1877.
63. Zweifel LS, Argilli E, Bonci A, Palmiter RD (2008) Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors. Neuron 59:486-496.